--- title: Ceryx Medical manufactures first implantable heart failure device at King’s College London’s MAISI facility description: Ceryx Medical has manufactured the first implantable device produced at MAISI, King’s College London’s national facility for active implant manufacture. image: https://news.lifesciencenewswire.com/hubfs/MAISI-facility.jpg --- [![Life Science Newswire 2](https://news.lifesciencenewswire.com/hs-fs/hubfs/Life%20Science%20Newswire%202.png?width=203&height=60&name=Life%20Science%20Newswire%202.png "Life Science Newswire 2")](https://lifesciencenewswire.com/) - [Newsroom](https://news.lifesciencenewswire.com/newsroom) - [Back to the main site](https://lifesciencenewswire.com/) ![LSNewswire-main-header-banner-v2-1](https://news.lifesciencenewswire.com/hubfs/LSNewswire-main-header-banner-v2-1.jpg "LSNewswire-main-header-banner-v2-1") # Newsroom #### Categories ![Arrow](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/sidebar.svg "Arrow") #### Subscribe![](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/subscribe-rss-button.svg) ![](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/close-button.svg) ### Choose a Category - [Agriculture (1)](https://news.lifesciencenewswire.com/newsroom/tag/agriculture) - [AI (2)](https://news.lifesciencenewswire.com/newsroom/tag/ai) - [Analytical Chemistry (42)](https://news.lifesciencenewswire.com/newsroom/tag/analytical-chemistry) - [Biomanufacturing (35)](https://news.lifesciencenewswire.com/newsroom/tag/biomanufacturing) - [biopharma (23)](https://news.lifesciencenewswire.com/newsroom/tag/biopharma) - [Bioprocessing (16)](https://news.lifesciencenewswire.com/newsroom/tag/bioprocessing) - [Biotechnology (252)](https://news.lifesciencenewswire.com/newsroom/tag/biotechnology) - [Cell Culture (10)](https://news.lifesciencenewswire.com/newsroom/tag/cell-culture) - [Clinical Diagnostics (38)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-diagnostics) - [clinical research (6)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research) - [Clinical Research & Trials (117)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research-trials) - [Computing & Technology (62)](https://news.lifesciencenewswire.com/newsroom/tag/computing-it) - [Corporate, Finance & Investor (288)](https://news.lifesciencenewswire.com/newsroom/tag/corporate-finance-investor) - [COVID-19 (86)](https://news.lifesciencenewswire.com/newsroom/tag/covid-19) - [Diagnostics & Hospital Laboratory (38)](https://news.lifesciencenewswire.com/newsroom/tag/diagnostics-hospital-laboratory) - [Digital Pathology (2)](https://news.lifesciencenewswire.com/newsroom/tag/digital-pathology) - [Drug Discovery & Development (153)](https://news.lifesciencenewswire.com/newsroom/tag/drug-discovery-development) - [Energy & Environment (15)](https://news.lifesciencenewswire.com/newsroom/tag/energy-environment) - [excipients (1)](https://news.lifesciencenewswire.com/newsroom/tag/excipients) - [Food & Beverage (8)](https://news.lifesciencenewswire.com/newsroom/tag/food-beverage) - [General Chemistry (7)](https://news.lifesciencenewswire.com/newsroom/tag/general-chemistry) - [General Laboratory (58)](https://news.lifesciencenewswire.com/newsroom/tag/general-laboratory) - [General Science (5)](https://news.lifesciencenewswire.com/newsroom/tag/general-science) - [Healthcare (136)](https://news.lifesciencenewswire.com/newsroom/tag/healthcare) - [Hospital Management (7)](https://news.lifesciencenewswire.com/newsroom/tag/hospital-management) - [Life Science (26)](https://news.lifesciencenewswire.com/newsroom/tag/life-science) - [Manufacturing (2)](https://news.lifesciencenewswire.com/newsroom/tag/manufacturing) - [Materials Science (2)](https://news.lifesciencenewswire.com/newsroom/tag/materials-science) - [Medical Devices & Technology (26)](https://news.lifesciencenewswire.com/newsroom/tag/medical-devices-technology) - [Microbiology & Infection Control (18)](https://news.lifesciencenewswire.com/newsroom/tag/microbiology-infection-control) - [Microscopy & Imaging (47)](https://news.lifesciencenewswire.com/newsroom/tag/microscopy-imaging) - [Nanotech (2)](https://news.lifesciencenewswire.com/newsroom/tag/nanotech) - [Omics & Genetics (87)](https://news.lifesciencenewswire.com/newsroom/tag/omics-genetics) - [Pathology (5)](https://news.lifesciencenewswire.com/newsroom/tag/pathology) - [Pharma (118)](https://news.lifesciencenewswire.com/newsroom/tag/pharma) - [Pharmacy (5)](https://news.lifesciencenewswire.com/newsroom/tag/pharmacy) - [Research (47)](https://news.lifesciencenewswire.com/newsroom/tag/research) - [Veterinary (6)](https://news.lifesciencenewswire.com/newsroom/tag/veterinary) - [Water (8)](https://news.lifesciencenewswire.com/newsroom/tag/water) See all ### Subscribe to Email Updates - ##### SHARE - - - # [Ceryx Medical manufactures first implantable heart failure device at King’s College London’s MAISI facility](https://news.lifesciencenewswire.com/newsroom/ceryx-medical-manufactures-first-implantable-heart-failure-device-at-kings-college-londons-maisi-facility) October 22, 2026 *A first for both organisations: the first implantable device built by the UK’s national active implant manufacturing facility is Ceryx’s bioelectronic pacemaker for heart failure* *![MAISI-facility](https://news.lifesciencenewswire.com/hs-fs/hubfs/MAISI-facility.jpg?width=557&height=299&name=MAISI-facility.jpg)* Ceryx Medical (Ceryx), the bioelectronic medtech company developing a new class of heart failure therapy, and King’s College London today announced that the first implantable device has been manufactured at MAISI, the national facility for the Manufacture of Active Implants and Surgical Instruments. The device is Ceryx’s implantable bioelectronic pacemaker, designed to restore the natural coupling between breathing and heart rhythm in patients with heart failure. It is the first implantable device Ceryx has manufactured, and the first implantable device MAISI has produced since the facility opened — a significant milestone for both organisations. Located at the St Thomas’ MedTech Hub in London, MAISI was established by King’s College London’s School of Biomedical Engineering & Imaging Sciences, in partnership with UCL and Newcastle University, with the support of a £5.2 million grant from Wellcome, and opened in 2023. It operates two ISO-7 cleanrooms within a certified quality management system, and exists to address a long-standing gap in the UK: the lack of specialised, regulated manufacturing capacity for complex active implants intended for human studies. That gap has historically forced UK companies developing active implantable devices to look overseas for small-batch manufacture, adding cost and delay at the most fragile stage of a company’s development. Building the device at MAISI has allowed Ceryx to manufacture under a certified quality system in the UK, alongside the regulatory expertise needed to support the route to clinical use. Dr Stuart Plant, CEO of Ceryx Medical, said: “Seeing the first implantable device come off the line is a moment the whole team has worked towards for years. It matters a great deal that we were able to do it here in the UK. MAISI is exactly the kind of infrastructure this country has been missing, and the fact that a Welsh company can build an active implantable device in London, under a certified quality system, with a regulatory team alongside, says something important about where UK medtech is heading.” Professor Anne Vanhoestenberghe, Professor of Active Implantable Medical Devices at King’s College London and Director of MAISI, said: “MAISI was built for precisely this — to give UK innovators a route from a promising design to a device manufactured to the standards that clinical translation demands. Producing our first implantable device with Ceryx proves the facility works as it was intended to, and we are proud that the first one through is a device with the potential to change the outlook for people living with heart failure.” Heart failure affects more than 20 million people across Europe and the US and remains the leading cause of hospitalisation in people over 65. Once diagnosed the condition is difficult to halt, with around half of patients dying within five years. Ceryx’s technology is designed to improve the efficiency of the failing heart and to support the heart’s own repair mechanisms. The milestone follows the completion of Ceryx’s RSA-Pace clinical study, led by Professor Zaheer Yousef OBE, who has recently joined the company as Chief Medical Officer. In the study, Ceryx’s biomimetic pacing was delivered to patients via an external pacing system; full results will be reported in due course. The new implantable device now enters preclinical testing, ahead of a study to demonstrate its full benefit to patients. Ceryx Medical has attracted interest from partners and investors in the UK and abroad, with backing from leading medtech investors including BGF, Parkwalk Advisors and the Development Bank of Wales.   **About Ceryx Medical** Ceryx Medical is developing a new class of bioelectronic devices that treat heart failure by restoring the body’s natural pacing rhythms. Spun out of research from the Universities of Bristol, Bath and Auckland and headquartered in Cardiff, the company’s mission is to harness the power of biomimicry to improve cardiovascular outcomes and quality of life for millions of patients worldwide. **About MAISI** MAISI is the national facility for the Manufacture of Active Implants and Surgical Instruments, located at the St Thomas’ MedTech Hub in London. It provides specialised and regulated facilities for the manufacture of Class IIb and Class III medical devices — including active implantable medical devices and complex surgical instruments — for first-in-human studies in the UK, together with dedicated regulatory support for compliance with UK MHRA requirements. MAISI was established by King’s College London’s School of Biomedical Engineering & Imaging Sciences in partnership with UCL and Newcastle University, supported by a £5.2 million grant from Wellcome, and opened in 2023. Categories: [Biomanufacturing](https://news.lifesciencenewswire.com/newsroom/tag/biomanufacturing), [Healthcare](https://news.lifesciencenewswire.com/newsroom/tag/healthcare), [Clinical Research & Trials](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research-trials), [Medical Devices & Technology](https://news.lifesciencenewswire.com/newsroom/tag/medical-devices-technology) ##### Browse more news ## Recent releases #### [Ceryx Medical manufactures first implantable heart failure device at King’s College London’s MAISI f...](https://news.lifesciencenewswire.com/newsroom/ceryx-medical-manufactures-first-implantable-heart-failure-device-at-kings-college-londons-maisi-facility) October 22, 2026 A first for both organisations: the first implantable device built by the UK’s national active implant manufacturing facility is Ceryx’s bioelectronic... ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/ceryx-medical-manufactures-first-implantable-heart-failure-device-at-kings-college-londons-maisi-facility) #### [Scope’s CRISPR Molecular Diagnostics CE Marked for Antifungal Resistance](https://news.lifesciencenewswire.com/newsroom/scopes-crispr-molecular-diagnostics-ce-marked-for-antifungal-resistance) October 6, 2026 Developed with AmplexDiagnostics, eazySNP brings scopeDx® into human diagnostics Scope Biosciences B.V., a Wageningen University spinoff life sciences... ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/scopes-crispr-molecular-diagnostics-ce-marked-for-antifungal-resistance) #### [CellCarta Establishes Strategic Partnership with Waters to Advance Companion Diagnostics Development](https://news.lifesciencenewswire.com/newsroom/cellcarta-establishes-strategic-partnership-with-waters-to-advance-companion-diagnostics-development) October 5, 2026 Collaboration combines CellCarta’s global clinical trial testing capabilities with Waters’ standardized flow cytometry platforms and expertise CellCar... ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/cellcarta-establishes-strategic-partnership-with-waters-to-advance-companion-diagnostics-development) ![LS-Newswire-reverse](https://news.lifesciencenewswire.com/hs-fs/hubfs/raw_assets/public/LifeScienceNewswire_June2020/images/LS-Newswire-reverse.png?width=150&name=LS-Newswire-reverse.png "LS-Newswire-reverse") Life Science Newswire is a division of BioStrata Ltd, with company registered address: 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, England, WA14 2DT. Company registration number: 8233225  #### Useful information - [Cookie and privacy policy](https://lifesciencenewswire.com/cookie-privacy-policy/) - [Website terms and conditions](https://lifesciencenewswire.com/terms-and-conditions) - [Promotion terms and conditions](https://lifesciencenewswire.com/promotion_terms/)